Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

NCT00891670 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Stenosis
Maximal Platelet Aggregation
Late Platelet Aggregation
High Post-Treatment Platelet Reactivity

Interventions

DRUG: cilostazol
DRUG: clopidogrel
DRUG: aspirin

Sponsor

Gyeongsang National University Hospital